Breast cancer CTC paper summary: what the automated negative selection platform revealed
See why CSV+ CTCs stood out in this study and what the results suggest for metastatic-risk stratification and recurrence monitoring.
Resource Center
Insights
Browse Good Future’s public CTC insights, from detection principles and enrichment methods to how reports are interpreted.
Insights
All Insights
5 published articles
Circulating Tumor Cell Detection: A new trend in precision cancer care
See how CTCs enter the bloodstream from primary tumors and why circulating tumor cell testing is becoming an important reference for cancer risk assessment and follow-up.
Exclusive negative selection technology retains more CTC phenotypes
From blood-cell removal and white-blood-cell identification to PowerMag magnetic-column processing, understand how Good Future reduces loss caused by relying on a single marker.
Why both epithelial and mesenchymal phenotypes matter
Tumor cells will undergo phenotypic changes during the metastasis process. If you only rely on a single positive expression, you may miss more risky cell populations.
From a 2 mL blood sample to a report in 5 business days
From 2 mL blood collection and pre-processing to complete cell imaging reports, understand how Good Future strings together the process into readable test results.